Literature DB >> 11520498

Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line.

L Iacovitti1, N D Stull, H Jin.   

Abstract

Previous studies from this laboratory have demonstrated that fibroblast growth factor 1 together with a number of co-activator molecules (dopamine, TPA, IBMX/forskolin), will induce the expression of the catecholamine biosynthetic enzyme tyrosine hydroxylase (TH) in 10% of human neurons (hNTs) derived from the NT2 cell line [10]. In the present study, we found that TH induction was increased to nearly 75% in hNTs when cells were permitted to age 2 weeks in culture prior to treatment with the differentiation cocktail. This high level of TH expression was sustained 7 days after removal of the differentiating agents from the media. Moreover, the induced TH present in these cells was enzymatically active, resulting in the production of low levels of dopamine (DA) and its metabolite DOPAC. These findings suggest that hNTs may provide an important tissue culture model for the study of factors regulating TH gene expression in human neurons. Moreover, hNTs may serve, in vivo, as a source of human DA neurons for use in transplantation therapies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520498     DOI: 10.1016/s0006-8993(01)02723-8

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

Review 1.  Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease.

Authors:  Yossef S Levy; Merav Stroomza; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

2.  Transient differentiation of adult human bone marrow cells into neuron-like cells in culture: development of morphological and biochemical traits is mediated by different molecular mechanisms.

Authors:  Sokreine Suon; Hao Jin; Angela E Donaldson; E J Caterson; Rocky S Tuan; Geoffrey Deschennes; Cheryl Marshall; Lorraine Iacovitti
Journal:  Stem Cells Dev       Date:  2004-12       Impact factor: 3.272

3.  Studies on the differentiation of dopaminergic traits in human neural progenitor cells in vitro and in vivo.

Authors:  Ming Yang; Angela E Donaldson; Cheryl E Marshall; James Shen; Lorraine Iacovitti
Journal:  Cell Transplant       Date:  2004       Impact factor: 4.064

4.  Purified mouse dopamine neurons thrive and function after transplantation into brain but require novel glial factors for survival in culture.

Authors:  A E Donaldson; C E Marshall; Ming Yang; S Suon; Lorraine Iacovitti
Journal:  Mol Cell Neurosci       Date:  2005-09       Impact factor: 4.314

5.  Factors influencing the differentiation of dopaminergic traits in transplanted neural stem cells.

Authors:  Ming Yang; Angela E Donaldson; Yubao Jiang; Lorraine Iacovitti
Journal:  Cell Mol Neurobiol       Date:  2003-10       Impact factor: 5.046

6.  Roles of db-cAMP, IBMX and RA in aspects of neural differentiation of cord blood derived mesenchymal-like stem cells.

Authors:  Murni Tio; Kian Hwa Tan; Wendy Lee; Ting Ting Wang; Gerald Udolph
Journal:  PLoS One       Date:  2010-02-24       Impact factor: 3.240

7.  Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats.

Authors:  Jingli Cai; Ming Yang; Elizabeth Poremsky; Sarah Kidd; Jay S Schneider; Lorraine Iacovitti
Journal:  Stem Cells Dev       Date:  2010-07       Impact factor: 3.272

8.  Molecular Mechanisms Involved in Neural Substructure Development during Phosphodiesterase Inhibitor Treatment of Mesenchymal Stem Cells.

Authors:  Jerome Fajardo; Bruce K Milthorpe; Jerran Santos
Journal:  Int J Mol Sci       Date:  2020-07-09       Impact factor: 5.923

9.  Differentiation of human bone marrow stem cells into cells with a neural phenotype: diverse effects of two specific treatments.

Authors:  Franca Scintu; Camilla Reali; Rita Pillai; Manuela Badiali; Maria Adele Sanna; Francesca Argiolu; Maria Serafina Ristaldi; Valeria Sogos
Journal:  BMC Neurosci       Date:  2006-02-16       Impact factor: 3.288

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.